

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Turtle Cameron</u> (Last) (First) (Middle) C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Eidos Therapeutics, Inc. [EIDX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ Officer (give title below) <input checked="" type="checkbox"/> _____ 10% Owner Other (specify below) <u>Chief Business Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/15/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/15/2020		M		4,451	A	\$17	55,072	D	
Common Stock	12/15/2020		M		21,843	A	\$13.2	76,915	D	
Common Stock	12/15/2020		S		3,756	D	\$110.2906 ⁽¹⁾	73,159	D	
Common Stock	12/15/2020		S		7,600	D	\$111.3075 ⁽²⁾	65,559	D	
Common Stock	12/15/2020		S		11,445	D	\$112.1903 ⁽³⁾	54,114	D	
Common Stock	12/15/2020		S		3,493	D	\$112.9657 ⁽⁴⁾	50,621	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$17	12/15/2020		M			4,451	(5)	06/20/2028	Common Stock	4,451	\$0.00	9,469	D	
Stock Option (Right to Buy)	\$13.2	12/15/2020		M			21,843	(6)	11/05/2028	Common Stock	21,843	\$0.00	53,157	D	

Explanation of Responses:

- Represents the weighted average sale price of the shares sold from \$109.71 to \$110.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 4.
- Represents the weighted average sale price of the shares sold from \$110.73 to \$111.71 per share.
- Represents the weighted average sale price of the shares sold from \$111.73 to \$112.72 per share.
- Represents the weighted average sale price of the shares sold from \$112.73 to \$113.59 per share.
- 25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
- The shares subject to this option vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Remarks:

/s/ Franco Valle, Attorney-in-Fact 12/16/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.